Regeneron Pharmaceuticals, Inc. company logo

# 1st Gen Model Regeneron Pharmaceuticals, Inc. Pharmaceutical preparations

60.81% successful of 74 deals
$478.65 Last close price
at 22-aug-2017

REGN

Model's trade recommendations 5.63% Return for period

-1.93% Annual return

$49.93B Market Cap

β 1.66  

REGN

Model (following trade recommendations)

REGN

Underlying stock

S&P 500

Index
Return for period 5.63%
-7.17%
1.78%
52wk return 8.31%
13.80%
16.82%
52wk Range
336.01—526.53
2000.54—2399.63
Sortino ratio -0.06
Sharpe ratio -0.05
Norm. RMSE 0.81%
Downside risk 12.52%
Volatility 17.11%
  • BUY Analysts consensus recommendation

Regeneron Pharmaceuticals Inc. is a biopharmaceutical company that discovers, develops, and intends to commercialize therapeutic drugs for thetreatment of serious medical conditions. Regeneron's platform technologies include Targeted GenomicsTM, FunctionomicsTM, and Designer Protein TherapeuticsTM. Regeneron has drugs in clinical and preclinical development for the potential treatment of obesity, rheumatoid arthritis, cancer, allergies, asthma, amyotrophic lateral sclerosis, constipating conditions, ischemia, and other diseases and disorders. (PRESS RELEASE)

Industry sector: Medical

Sector classification: Pharmaceutical preparations

Deep Learning based analysis and prediction model for Regeneron Pharmaceuticals, Inc. (REGN) stock is a 1st Generation Non-linear Autoregresive with exogenous variable(s) (NARX) model based on the Recurrent Neural Network architecture.

Model is in the production pipeline since Oct. 22, 2015.

Market data for REGN model training are being downloaded from the Quandl premium datasets on a daily basis.

Model is being retrained on a daily basis.

Float 95M
P/E 44.15
Shares Outstanding 106M
% Held by Insiders 10.40%
% Held by Institutions 67.16%
EPS (last reported FY) $8.26
EPS (last reported Q) $3.88
EPS, estimated (last reported Q) $2.67
Total revenues $5 B
Net income $1 B